Enzyme replacement therapy for Fabry disease: Proving the clinical benefit

Nephrology Dialysis Transplantation

Volumn 18, Issue 1, 2003, Pages 7-9

  Breunig, Frank ^a   Wanner, Christoph ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Clinical trial; Enzyme replacement; Fabry disease; Genetic disorders; Lysosomal storage disease

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GALACTOSIDASE; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; CARBAMAZEPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GABAPENTIN; GLOBOTRIAOSYLCERAMIDE; GLYCOSPHINGOLIPID; PHENYTOIN;

ARTIFICIAL HEART PACEMAKER; CARDIOMYOPATHY; CELL DAMAGE; CEREBROVASCULAR DISEASE; CHRONIC PAIN; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FABRY DISEASE; GENE THERAPY; GENETIC ENGINEERING; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HEMATURIA; HUMAN; KIDNEY FAILURE; KIDNEY GRAFT; LIPID METABOLISM; LYSOSOME STORAGE DISEASE; ONSET AGE; PRIORITY JOURNAL; PROTEINURIA; X CHROMOSOME LINKED DISORDER;

ALPHA-GALACTOSIDASE; CLINICAL TRIALS; ENZYMES; FABRY DISEASE; HUMANS; REPRODUCIBILITY OF RESULTS;

EID: 0037234314     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/18.1.7     Document Type: Editorial

References (24)

1. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AI, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th edn. Vol. 3. New York: McGraw-Hill; 2001: 3733-3774
2. Moore DF, Altaresu G, Geoffrey SF et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002; 33: 525-531
3. Thadhani R, Wolf M, West ML et al. Patients with Fabry disease on dialysis in the United States. Kidney, Int 2002; 61: 249-255
4. Linhart A, Palecek T, Bultas J et al. New insights in cardiac structural changes in patients with Fabry disease. Am Heart J 2000; 139: 1101-1108
5. Tanaka H, Adachi K, Yamashita J, Toshima H, Koga Y. Four cases of Fabry's disease mimicking hypertrophic cardiomyopathy. J Cardiol 1988; 18: 705-718
6. Cantor WJ, Butany J, Cusimao RJ, Iwanochko M. Restrictive cardiomyopathy secondary to Fabry's disease. Circulation 1998; 98: 1457-1459
7. von Scheidt W, Eng CM, Fitzmaurice TF et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991; 324: 395-399
8. Cantor WJ, Daly P, Iwanochko M, Clarke JT, Cusimano RJ, Butany J. Cardiac transplantation for Fabry disease. Can J Cardiol,1998; 14: 81-84
9. Pochis WT, Litzow JT, King BG, Kenny D. Electrophysiologic findings in Fabry's disease with a short PR interval. Am J Cardiol 1994; 74: 203-204
10. Sachdev B, Takenaka T, Teraguchi H et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002; 105: 1407-1411
11. Eckart RE, Kinney KG, Belnap CM, Le TD. Ventricular fibrillation refractory to automatic internal cardiac defibrillator in Fabry's disease. Cardiology 2000; 94: 208-212
12. Mitsias P, Levine SR. Cerebrovascular complications of Fabry's disease. Ann Neurol 1996; 40: 8-17
13. Mendez MF, Stanley TM, Medel NM, Li Z, Tedesco DT. The vascular dementia of Fabry's disease. Dement Geriatr Cogn Disord 1997; 8: 252-257
14. Ojo A, Meier-Kriesche HU, Friedman G et al. Excellent outcome of renal transplantation in patients with Fabry's disease. Transplantation 2000; 69: 2337-2339
15. Sessa A, Meroni M, Battini G et al. Renal transplantation in patients with Fabry disease. Nephron 2002; 91: 348-351
16. Jung SC, Han IP, Limaye A, Xu R, Geldermann MP, Zerfas P. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of fabry mice. Proc Natl Acad Sci USA 2001; 98: 2676-2681
17. Bishop DF, Calhoun DH, Bernstein, Hanzopoulos P, Quinn M, Desnick RJ. Human α-galactosidase A: Nucleotide sequence of a c DNA clone encoding the mature enzyme. Proc Natl Acad Sci USA 1986; 83: 4859-4863
18. Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M. Infusion of α galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 2000; 97: 365-370
19. Schiffmann R, Kopp JB, Austin HA III et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285: 2743-2749
20. Eng CM, Banikazemi M, Gordon RE et al. A phase I/II clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001; 68: 711-722
21. Eng CM, Guffon N, Wilcox WR et al. Safety and efficacy of recombinant human α-galactosidase A replacement in Fabry disease. N Engl J Med 2001; 345: 9-16
22. De Schoenmakere G, Chauveau D, Grünfeld J-P. Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function. Nephrol Dial Transplant 2003; 18: 33-35
23. Whybra C, Kampmann C, Willers I et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001; 24: 715-724
24. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995; 333: 288-293